Transcatheter aortic valve implantation with the repositionable and fully retrievable Lotus Valve System TM

Transcatheter aortic valve implantation (TAVI) has become a therapeutic alternative for patients presenting with severe symptomatic aortic stenosis and considered either at high (1,2) or intermediate preoperative risk (3,4) for surgical aortic valve replacement (SAVR). Recent recommendations found that transfemoral TAVI, in comparison to SAVR, results in lower mortality and acute kidney injury at 2 years, and may reduce stroke rates (5). Over the past 15 years, several transcatheter devices have been tested and evolved to decrease access site complications with smaller profile delivery systems, decrease pacemaker rates, and avoid the risk of coronary obstruction and significant paravalvular leakage (PVL) (6-9)